NCT07002164 Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
| NCT ID | NCT07002164 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chonnam National University Hospital |
| Condition | Myocardial Infarction (MI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 780 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2030-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 780 participants in total. It began in 2025-07-15 with a primary completion date of 2030-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study objectives: To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization. Study hypothesis: Immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization. Background: Although current guidelines recommend early CAG within 2 hours for patients with NSTEMI complicated by AHF, many patients with NSTEMI complicated by AHF did not receive early CAG. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF. Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \<2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF. Study procedure: Following the establishment of NSTEMI diagnosis, participants fulfilling the eligibility criteria will be randomized at a ratio of 1:1 to immediate CAG ≤2 hours after randomization or delayed CAG after stabilization on another day during hospitalization.
Eligibility Criteria
Inclusion Criteria: * Age ≥19 years * Non-ST-segment elevation myocardial infarction * New-onset or worsening of dyspnea (New York Heart Association class ≥2) * Pulmonary congestion * Patient's or guardian's consent after understanding the study Exclusion Criteria: * Cardiogenic shock at initial presentation * ST-segment elevation myocardial infarction * ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or * New onset left bundle branch block * Posterior wall myocardial infarction * Refractory angina * Life threatening ventricular arrhythmias * Life expectancy \<1 year * Apparently non-ischemic cause of HF * Pregnancy and lactation * History of coronary artery bypass grafting (CABG), or planned CABG * Patient's refusal to participate in study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07002164 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Myocardial Infarction (MI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07002164 currently recruiting?
Yes, NCT07002164 is actively recruiting participants. Contact the research team at cecilyk@hanmail.net for enrollment information.
Where is the NCT07002164 trial being conducted?
This trial is being conducted at Changwon, South Korea, Daegu, South Korea, Daegu, South Korea, Daegu, South Korea and 11 additional locations.
Who is sponsoring the NCT07002164 clinical trial?
NCT07002164 is sponsored by Chonnam National University Hospital. The trial plans to enroll 780 participants.